This episode From the Vault comes from last year’s SurfingNASH review of the 2022 NAFLD Summit with Mazen Noureddin, Sven Francque and Hannes Hagström.
The 2022 NAFLD Summit uniquely presented a range of perspectives and insights on fatty liver and metabolic diseases.
The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD. In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.
This week, SurfingNASH offers an episode comprising two separate interviews which focus on stories around career trajectories, transitions and entrepreneurship.
The EASL SLD Summit aims at updating a global community of liver stakeholders on the most recent advances in SLD research, both pre-clinically and clinically, focusing on MASLD and tackling the issue of MetALD.
In this episode, Jörn Schattenberg, Louise Campbell and Roger Green review the recently concluded meeting with faculty members Sven Francque and Hannes Hagström in two seperate interviews.
Surfing NASH reviews the 2023 EASL SLD Summit in two interview sessions with meeting faculty members Sven Francque and Hannes Hagström. Co-host Jörn Schattenberg joins both conversations as a fellow presenter while Louise Campbell and Roger Green inject thought-provoking questions and perspectives to elicit a succinct snapshot of the event for our listeners.
In this episode From the Vault, Jörn Schattenberg joins Stephen Harrison and Roger Green to review some highlights from the 2021 Paris NASH meeting, an event with exciting scientific messages and insights. This episode has played out to be by far the most downloaded segment in the podcast’s history!
In this final conversation, the Surfers are joined by Veronica Miller to discuss the recent FDA workshop for NIT development. Veronica discusses her unique impressions on the workshop and steers the group to consider the question of “why are we validating a surrogate with a surrogate?”
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. This discussion largely focuses on ideas around distinguishing the difference between NITs to qualify patients for trials versus to evaluate efficacy of drugs.
In this conversation, the Surfers are joined by Laurent Castera to discuss the recent FDA workshop for NIT development. Laurent focuses on why this workshop is important within its context of being hosted by the FDA and what that means for researchers and stakeholders across the globe. He also dives into the complexities of hepatocellular ballooning and its potential impact on patients receiving NASH pharmacotherapy.
In this conversation, the Surfers are joined by Naim Alkhouri to discuss the recent FDA workshop for NIT development. Naim expands on ideas around an NIT-based alternative path to conditional approval as well as provides a general survey of how the workshop played out as he served as an expert panelist in Tuesday’s penultimate session.
